COVID-19 Vaccination In Autoimmune Diseases (COVAD) Study : Vaccine Safety In Idiopathic Inflammatory Myopathies
Gil-Vila, Albert (Hospital Universitari Vall d'Hebron)
Naveen, R. (Sanjay Gandhi Postgraduate Institute of Medical Sciences)
Selva O'Callaghan, Albert (Hospital Universitari Vall d'Hebron)
Sen, Parikshit (Maulana Azad Medical College)
Nune, Arvind (Southport and Ormskirk Hospital NHS Trust)
Gaur, Prithvi Sanjeevkumar (Smt. Kashibai Navale Medical and General Hospital)
Gonzalez, Raquel Arànega (Hospital Clínic i Provincial de Barcelona)
Lilleker, James B. (Northern Care Alliance NHS Foundation Trust)
Joshi, Mrudula (Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals)
Agarwal, Vishwesh (Mahatma Gandhi Mission Medical College)
Kardes, Sinan (Istanbul University)
Kim, Minchul (University of Illinois College of Medicine Peoria)
Day, Jessica (University of Melbourne)
Makol, Ashima (Mayo Clinic)
Milchert, Marcin (Pomeranian Medical University in Szczecin, ul Unii Lubelskiej 1)
Gheita, Tamer (Cairo University)
Salim, Babur (Fauji Foundation Hospital)
Velikova, Tsvetelina (Sofia University St. Kliment Ohridski)
Gracia-Ramos, Abraham Edgar (National Medical Center "La Raza")
Parodis, Ioannis (Örebro University)
Nikiphorou, Elena (King's College Hospital NHS Foundation Trust)
Tan, Ai Lyn (University of Leeds)
Chatterjee, Tulika (University of Illinois College of Medicine Peoria)
Cavagna, Lorenzo (Università degli studi di Pavia)
Saavedra, Miguel A. (Centro Médico Nacional La Raza)
Shinjo, Samuel Katsuyuki (Universidade de Sao Paulo)
Ziade, Nelly (Hotel-Dieu de France Hospital)
Knitza, Johannes (Universitätsklinikum Erlangen)
Kuwana, Masataka (Nippon Medical School Graduate School of Medicine)
Distler, Oliver (University Hospital Zurich (Suïssa))
Chinoy, Hector (Salford Royal Hospital Northern Care Alliance NHS Foundation Trust)
Agarwal, Vikas (Sanjay Gandhi Postgraduate Institute of Medical Sciences)
Aggarwal, Rohit (University of Pittsburgh School of Medicine)
Gupta, Latika (The University of Manchester)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	In this study we investigated COVID-19 vaccination-related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs). Seven-day vaccine ADEs were collected in an international patient self-reported e-survey. Descriptive statistics were obtained and multivariable regression was performed. Ten thousand nine hundred respondents were analyzed (1227 IIM cases, 4640 SAID cases, and 5033 healthy controls [HCs]; median age, 42 [interquartile range, 30-455] years; 74% female; 45% Caucasian; 69% completely vaccinated). Major ADEs were reported by 76. 3% of the IIM patients and 4. 6% reported major ADEs. Patients with active IIMs reported more frequent major (odds ratio [OR], 2. 7; interquartile range [IQR], 1. 04-7. 3) and minor (OR, 1. 5; IQR, 1. 1-2. 2) ADEs than patients with inactive IIMs. Rashes were more frequent in IIMs (OR, 2. 3; IQR, 1. 2-4. 2) than HCs. ADEs were not impacted by steroid dose, although hydroxychloroquine and intravenous/subcutaneous immunoglobulins were associated with a higher risk of minor ADEs (OR, 1. 9; IQR, 1. 1-3. 3; and OR, 2. 2; IQR, 1. 1-4. 3, respectively). Overall, ADEs were less frequent in inclusion-body myositis (IBM) and BNT162b2 (Pfizer) vaccine recipients. Seven-day postvaccination ADEs were comparable in patients with IIMs, SAIDs, and HCs, except for a higher risk of rash in IIMs. Patients with dermatomyositis with active disease may be at higher risk, and IBM patients may be at lower risk of specific ADEs. Overall, the benefit of preventing severe COVID-19 through vaccination likely outweighs the risk of vaccine-related ADEs. Our results may inform future guidelines regarding COVID-19 vaccination in patients with SAIDs, specifically in those with IIMs. Studies to evaluate long-term outcomes and disease flares are needed to shed more light on developing future COVID-19 vaccination guidelines.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	COVID-19 ; Dermatomyositis ; Myositis ; Rheumatology ; Vaccination
Publicat a:	Muscle & nerve, july 2022, ISSN 1097-4598

DOI: 10.1002/mus.27681
PMID: 35869701

12 p, 2.8 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats